NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD
NASDAQ:OCX (5/1/2025, 9:22:34 PM)
3.1
+0.02 (+0.65%)
The current stock price of OCX is 3.1 USD. In the past month the price increased by 5.08%. In the past year, price increased by 16.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.83 | 342.01B | ||
AMGN | AMGEN INC | 14.32 | 152.57B | ||
GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
REGN | REGENERON PHARMACEUTICALS | 13.32 | 64.50B | ||
ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
NTRA | NATERA INC | N/A | 20.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
BIIB | BIOGEN INC | 7.34 | 17.70B |
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
ONCOCYTE CORP
15 Cushing
Irvine CALIFORNIA 92618 US
CEO: Ronald Andrews
Employees: 45
Company Website: https://oncocyte.com/
Investor Relations: https://investors.oncocyte.com/
Phone: 19494097600
The current stock price of OCX is 3.1 USD. The price increased by 0.65% in the last trading session.
The exchange symbol of ONCOCYTE CORP is OCX and it is listed on the Nasdaq exchange.
OCX stock is listed on the Nasdaq exchange.
8 analysts have analysed OCX and the average price target is 4.51 USD. This implies a price increase of 45.32% is expected in the next year compared to the current price of 3.1. Check the ONCOCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ONCOCYTE CORP (OCX) has a market capitalization of 88.66M USD. This makes OCX a Micro Cap stock.
ONCOCYTE CORP (OCX) currently has 45 employees.
ONCOCYTE CORP (OCX) has a support level at 2.87 and a resistance level at 3.35. Check the full technical report for a detailed analysis of OCX support and resistance levels.
The Revenue of ONCOCYTE CORP (OCX) is expected to grow by 104.75% in the next year. Check the estimates tab for more information on the OCX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OCX does not pay a dividend.
ONCOCYTE CORP (OCX) will report earnings on 2025-05-13, before the market open.
ONCOCYTE CORP (OCX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.4).
The outstanding short interest for ONCOCYTE CORP (OCX) is 1.81% of its float. Check the ownership tab for more information on the OCX short interest.
ChartMill assigns a technical rating of 8 / 10 to OCX. When comparing the yearly performance of all stocks, OCX is one of the better performing stocks in the market, outperforming 94.85% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OCX. OCX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months OCX reported a non-GAAP Earnings per Share(EPS) of -4.4. The EPS decreased by -22.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -173.67% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 75% to OCX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 75.47% and a revenue growth 104.75% for OCX